Showing results (41-50 of 88) with videos related to
Sort By:
Pageof 9
Drug Testing and Analysis|January 3, 2023
Determination of cannabinoids content in light cannabis inflorescences sold in FranceNicolas Fabresse, Marc Faltot, Perrine Roux, et al.Clinical Pharmacokinetics|April 28, 2006
Population pharmacokinetics of ceftriaxone and pharmacodynamic considerations in haemodialysed patientsNicolas Simon, Bertrand Dussol, Emmanuelle Sampol, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|December 1, 2012
Renal impairment in patients receiving a tenofovir-cART regimen: impact of tenofovir trough concentrationIsabelle Poizot-Martin, Caroline Solas, Julie Allemand, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|March 28, 2002
High indinavir Cmin is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimenCaroline Solas, Stéphanie Basso, Isabelle Poizot-Martin, et al.Therapeutic Drug Monitoring|November 9, 2020
Development and Validation of a Simple and Rapid Ultrahigh-Performance Liquid Chromatography Tandem Spectrometry Method for the Quantification of Hydroxychloroquine in Plasma and Blood Samples in the Emergency Context of SARS-CoV-2 PandemicNatalia Doudka, Madeleine Giocanti, Manon Basso, et al.Pharmacogenetics and Genomics|April 9, 2015
Lethal toxicity after administration of azacytidine: implication of the cytidine deaminase-deficiency syndromeRaphaelle Fanciullino, Cedric Mercier, Cindy Serdjebi, et al.Pharmacogenomics|July 11, 2013
Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimenCindy Serdjebi, Jean-François Seitz, Joseph Ciccolini, et al.British Journal of Clinical Pharmacology|September 23, 2015
Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancerManon Launay, Laetitia Dahan, Manon Duval, et al.British Journal of Clinical Pharmacology|October 14, 2017
Ledipasvir and tenofovir drug interaction in human immunodeficiency virus-hepatitis C virus coinfected patients: Impact on tenofovir trough concentrations and renal safetyCaroline Solas, Sylvie Bregigeon, Olivia Faucher-Zaegel, et al.Pharmacogenomics|March 3, 2012
CDA deficiency as a possible culprit for life-threatening toxicities after cytarabine plus 6-mercaptopurine therapy: pharmacogenetic investigationsJoseph Ciccolini, Alexandre Evrard, Lithaty M'Batchi, et al.Pageof 9